Quick Answer
Inhibikase Therapeutics, Inc. reported Operating Income of -$51.97 million for fiscal year 2025.
Inhibikase Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$51.97M | -81.8% |
| 2024 | -$28.59M | -42.3% |
| 2023 | -$20.09M | -10.8% |
| 2022 | -$18.13M | -22.8% |
| 2021 | -$14.77M | -423.9% |
| 2020 | -$2.82M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$12.77M | -119.1% | -17.9% |
| June 30, 2025 | -$10.83M | -114.5% | +25.8% |
| March 31, 2025 | -$14.60M | -205.2% | -150.5% |
| September 30, 2024 | -$5.83M | -22.2% | -15.4% |
| June 30, 2024 | -$5.05M | +18.6% | -5.6% |
| March 31, 2024 | -$4.78M | -1.4% | -0.3% |
| September 30, 2023 | -$4.77M | -5.7% | +23.1% |
| June 30, 2023 | -$6.20M | -33.7% | -31.5% |
- Inhibikase Therapeutics, Inc. showed a decrease of -81.8% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Inhibikase Therapeutics, Inc.’s operating income has declined by 1744.0% (from -$2.82 million to -$51.97 million).
- The most recent figure is from Inhibikase Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: